On July 13, PegBio (02565.HK) rose 8.42% in regular trading, trading at HKD 7.29/share, with turnover of HKD 108 million, extending the strong rally momentum from the previous Friday.

The sustained upside is driven by the memorandum of understanding signed on July 8 between PegBio and Nasdaq-listed Rani Therapeutics. Under the three-year agreement, the two companies will leverage Rani's proprietary RaniPill oral biologics delivery platform to conduct oral formulation screening and preclinical development for multiple innovative candidates in PegBio's obesity and metabolic disease pipeline. The parties also plan to explore cooperation in R&D, manufacturing, and commercialization of related products outside China. The collaboration adds a next-generation oral dosage form and overseas development pathway to PegBio's metabolic pipeline, with market sentiment continuing to build following the initial 35%+ surge on July 10 when the deal was first announced.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)